Stryker Corporation $SYK Shares Sold by Brasada Capital Management LP

Brasada Capital Management LP cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 58.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,264 shares of the medical technology company’s stock after selling 8,932 shares during the period. Brasada Capital Management LP’s holdings in Stryker were worth $2,181,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker during the 4th quarter valued at $27,000. DJE Kapital AG bought a new stake in shares of Stryker in the 4th quarter worth $28,000. Finally, Strive Asset Management LLC acquired a new stake in shares of Stryker in the third quarter valued at $30,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Evercore set a $355.00 target price on Stryker in a report on Friday, May 1st. William Blair reiterated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Citigroup dropped their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. BTIG Research dropped their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $395.33.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $312.14 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The stock has a fifty day moving average of $316.40 and a 200-day moving average of $343.97. The company has a market capitalization of $119.66 billion, a PE ratio of 36.13, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the company posted $2.84 EPS. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.